SOURCE: NuPathe Inc.

NuPathe Inc.

May 24, 2011 08:30 ET

NuPathe Strengthens Commercial Team

Preparing for 2012 Launch of Migraine Patch

CONSHOHOCKEN, PA--(Marketwire - May 24, 2011) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announced the appointments of Robert J. Murphy as Vice President of Sales and David T. McGovern as Head of Marketing.

Mr. Murphy is a seasoned sales and marketing executive with over 23 years of pharmaceutical industry experience. He most recently served as senior vice president, hospital & surgical products, for Pfizer, having held the same position at King Pharmaceuticals prior to its acquisition by Pfizer. Earlier in his career at King, Mr. Murphy held the position of senior vice president, field sales commercial operations, where he led King's $1.6 billion, 1,100 person U.S. primary care and specialty business. Prior to King, Mr. Murphy served in multiple senior leadership positions including national sales director, neurosciences for Novartis where he built a specialty sales force for the launch of several products.

Mr. McGovern also joined NuPathe from Pfizer, where he served as senior product director, Alzheimer's global marketing. In this role he led all commercial strategy and global market development for the Alzheimer's biologics franchise. During his impressive 17 year career in the pharmaceutical industry, Mr. McGovern has built and led several marketing teams including those with extensive e-marketing and patient focus. Prior to his most recent position, Mr. McGovern served in various roles at Wyeth Pharmaceuticals, Johnson & Johnson and Merck.

"We are thrilled to be welcoming two such accomplished, talented professionals to our management team," said, Jane H. Hollingsworth, chief executive officer of NuPathe. "Their great track record and expertise in successfully building teams and launching products, including significant neuroscience products, bolsters the commercial horsepower of NuPathe as we prepare for the launch of our migraine patch in the first half of 2012."

About Zelrix
Zelrix is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. Zelrix is designed to provide migraine patients fast onset and sustained relief through a tolerable, non-oral route of administration. Zelrix may provide an attractive treatment option for millions of migraine patients because it avoids the need for oral administration. Many migraine patients delay or avoid treatment with oral medications as a result of underlying migraine-related nausea and vomiting. In addition, the absorption of oral medications may be compromised during a migraine which may adversely affect the efficacy of such medications. Zelrix is powered by SmartRelief™, NuPathe's proprietary transdermal delivery technology. SmartRelief consists of a controlled delivery technology that uses a mild electrical current to actively transport medication through the skin using a process called iontophoresis.

About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's lead product candidate, Zelrix, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.

Cautionary Statement About Forward-Looking Information
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to the timing of, and preparedness for, the commercial launch of Zelrix and the potential benefits of Zelrix and NuPathe's other product candidates. Forward-looking statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from those indicated by the forward-looking statements contained herein including, among others: NuPathe's ability to obtain marketing approval for and commercialize Zelrix; serious adverse events or other safety risks that could require NuPathe to abandon or delay development of, or preclude or limit approval of, Zelrix or its other product candidates; varying interpretation of clinical and market data; and the risks, uncertainties and other factors discussed in NuPathe's Annual Report on Form 10-K for the year ended December 31, 2010 under the caption "Risk Factors" and elsewhere in such report, which is available on NuPathe's website at www.nupathe.com in the "Investor Relations - SEC Filings" section. While NuPathe may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. You are cautioned not to place undue reliance on any forward-looking statements.

Contact Information

  • INVESTOR CONTACTS:
    John Woolford
    (443) 213-0506
    Email Contact

    Keith A. Goldan
    Vice President, Chief Financial Officer
    NuPathe Inc.
    (484) 567-0130

    MEDIA CONTACTS:
    Jerry McLaughlin
    Vice President, Commercial Operations
    NuPathe Inc.
    (484) 567-0130